Trifluridine Tipiracil is a type of cancer chemotherapy medicine which falls under the group of medicines known as cytostatic antimetabolite medicines. This medicinal product is available as tablets under the brand-name Lonsurf. The trifluridine tipiracil tablet is a composition of two different active substances: trifluridine & tipiracil.
- Trifluridine helps stop the progression of cancer cells.
- Tipiracil helps stop the trifluridine from being broken down by the body, helping trifluridine to work longer.
Therapeutic Indications
Colorectal cancer:
Trifluridine Tipiracil is indicated as monotherapy to treat adult patients with metastatic colorectal cancer (CRC) who have been previously taken treatment, or are not considered candidates for, existing therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-EGFR agents and anti-VEGF agents.
Gastric cancer:
Trifluridine Tipiracil is indicated as monotherapy to treat adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously taken treatment with at least a couple of systemic treatment regimens for their advanced disease.
Posology and Method of Administration
Trifluridine Tipiracil combination (Lonsurf) should be prescribed by a health specialist experienced in the administration of anticancer therapy.
Posology:
The recommended lonsurf dosage is 35 mg/m2 up to a maximum of 80 mg/dose (depending on the trifluridine component) orally twice in a day with food on Days 1'st through 5'th and Days 8'th through 12'th of each 28-day cycle until the disease is progressive or unacceptable toxicity occurs. Round dose to the approximately 5 mg increment. Patients should swallow the Trifluridine/Tipiracil tablets whole. Patients are instructed not to retake doses of Trifluridine/Tipiracil that are missed or vomited and to continue with the very next scheduled dose. Trifluridine/Tipiracil (Lonsurf) is a cytotoxic medicine. Follow all the applicable special handling and disposal procedures.
Recommended Dose Adjustments:
Dose adjustments may be needed based on individual safety as well as tolerability. A maximum of three dose reductions are permitted to a minimum dose of 20 mg per m2 twice daily. Dose escalation is not authorized after it has been reduced.
Recommended Dosage for Renal Impairment:
In patients with severe renal impairment (CLcr of 15 to 29 mL/min as specified by the formula named Cockcroft-Gault), the standard dosage is 20 mg/m2 (depending on the trifluridine component) by mouth twice daily with meal on Days 1'st through 5'th and Days 8'th through 12'th of each 28-day cycle. Reduce the dose to 15 mg per m2 twice in a day in patients with severe renal impairment who are not able to tolerate a dose of 20 mg per m2 twice in a day. Permanently discontinue treatment with Trifluridine and Tipiracil in those patients who are not able to tolerate a dose of 15 mg per m2 twice in a day.
Method of Administration:
Trifluridine Tipiracil typically supplied in two strengths: 15 mg and 20 mg tablets. Your health specialist may prescribe both dosage strengths for your prescribed dose.
Trifluridine Tipiracil is available for oral use. These tablets must be taken through a glass of water within 60 minutes after taking morning and evening meals.
A pill you swallow twice daily with food- the type of food simply does not matter. A pill you swallow whole. It is not advisable to retake doses of Trifluridine Tipiracil that are missed or vomited and continue with the very next scheduled dose.
Prepare your treatment calendar: With this easy tool, patients can prepare and print a personalized Trifluridine Tipiracil treatment calendar where they can track their standard doses, temperature, and any adverse reaction they experience. Patients should share this calendar with their health specialist at their next appointment.
Note: If your health specialist changes your Trifluridine Tipiracil dosage, be sure to prepare a new treatment calendar.
